Arezou Mehrabi | biomedical science | Best Researcher Award

Posted on by ScienceFather

Assist. Prof. Dr Arezou Mehrabi | biomedical science | Best Researcher Award

Assist. Prof. Dr, Islamic Azad University – Tonekabon Branch, Iran

Arezou Mehrabi, born in Mazandaran, Iran, is a tissue engineering researcher known for her innovative work in biomedical materials. She completed her Ph.D. in Tissue Engineering at Iran University of Medical Sciences, focusing on bioactive hydrogels for wound healing. With a strong foundation in anatomical science (M.Sc.) from Tarbiat Modares University and a B.Sc. in Radiology from Mashhad University of Medical Sciences, Mehrabi’s research is primarily devoted to advancing regenerative medicine, particularly for cardiac and bone tissue applications. Her work includes various publications and collaborations, shaping her as a prominent figure in tissue engineering.

Publication Profile

scholar

Education 🎓

Mehrabi obtained her Ph.D. in Tissue Engineering from Iran University of Medical Sciences (2018-2023), presenting a thesis on in-situ forming hydrogels for wound healing. Previously, she earned an M.Sc. in Anatomical Science (2015-2017) from Tarbiat Modares University, focusing on electroactive carbon nanofiber cardiac patches. Her academic journey began with a B.Sc. in Radiology at Mashhad University of Medical Sciences (2011-2015). These academic credentials provided a strong multidisciplinary background, supporting her expertise in biomedical and tissue engineering.

Experience 💼

Mehrabi’s professional experience includes significant contributions to tissue engineering, with a specialization in electroactive and bioactive hydrogels. Her research has focused on applications in cardiac and bone regeneration, including projects on nanofiber cardiac patches and electroconductive scaffolds. She has collaborated on diverse projects and has presented her findings at numerous international conferences. Her work has also led to the development of patents in electroactive cardiac patches and innovative biomaterials for regenerative medicine.

Awards and Honors 🏆

Mehrabi has earned recognition for her contributions, including a certified patent for an electroactive cardiac patch awarded by the Iranian Research Organization for Science and Technology (IROST, Patent No. 94280). She has also co-authored influential studies and book chapters and contributed to significant scientific publications. Her dedication to research has positioned her as a key innovator in tissue engineering, especially in developing new materials for cardiac and bone tissue engineering.

Research Focus 🔬

Mehrabi’s research is centered on biomaterials for tissue engineering, with a focus on bioactive and electroactive materials for cardiac and wound healing applications. Her notable projects include developing carbon nanofiber-based cardiac patches and hydrogels that promote vascularization and regeneration. Mehrabi is also exploring advanced applications for natural polymers in cancer diagnosis and treatment. Her work in regenerative medicine aims to advance sustainable, innovative solutions for therapeutic applications in healthcare.

Publication Top Notes

Electroactive Cardiac Patch
Development of a novel electroactive cardiac patch based on carbon nanofibers and gelatin encouraging vascularization
A. Mehrabi, N. Baheiraei, M. Adabi, Z. Amirkhani
Applied Biochemistry and Biotechnology 190, 931-948, 47 citations (2020)

In-Situ Hydrogel for Wound Healing
In-situ forming hydrogel based on thiolated chitosan/carboxymethyl cellulose (CMC) containing borate bioactive glass for wound healing
A. Mehrabi, A. Karimi, S. Mashayekhan, A. Samadikuchaksaraei, PB Milan
International Journal of Biological Macromolecules 222, 620-635, 26 citations (2022)

Hydrogel for Breast Reconstruction
Synthesis and characterization of a silk fibroin/placenta matrix hydrogel for breast reconstruction
A. Mehrabi, S. Mousazadeh, A. Mollafilabi, N. Nafissi, PB Milan
Life Sciences 334, 122236, 7 citations (2023)

Bone Tissue Engineering
Evaluation of inherent properties of the carboxymethyl cellulose (CMC) for potential application in tissue engineering focusing on bone regeneration
A. Mehrabi, SZ Jalise, A. Hivechi, S. Habibi, MM Kebria, MA Haramshahi
Polymers for Advanced Technologies 35 (1), e6258, 5 citations (2024)

Vasculogenesis and Angiogenesis
Molecular mediators of vasculogenesis and angiogenesis
M. Amoupour, MM Kebria, A. Hivechi, N. Peyravian, M. Ghasemian
Biomaterials for Vasculogenesis and Angiogenesis, 13-37, 5 citations (2022)

Cell Sources in Cardiac Tissue Engineering
Cell sources in cardiac tissue engineering: current choices
PB Milan, N. Amini, A. Mehrabi, S. Mousazadeh, S. Ababzadeh, A. Rezapour
Current Stem Cell Research & Therapy 16 (6), 745-752, 5 citations (2021)

Electroconductive Scaffolds
Electroconductive Scaffolds: A New Strategy in Cardiac Tissue Engineering
A. Mehrabi, N. Baheiraei
Pathobiology Research 21 (2), 107-111, 2 citations (2018)

Natural Polymers in Cancer Treatment
Natural polymers for diagnosis and treatment of cancers
A. Mehrabi, R. Najafloo, H. Valizadeh, VH Sarmadi, S. Naderi
Biomaterials for Precision Cancer Medicine, 123-153, 2025

In Situ Fibrin Scaffold for Bone Engineering
Development of in situ forming autologous fibrin scaffold incorporating synthetic teriparatide peptide for bone tissue engineering
MR Khalili, A. Molafilabi, S. Mousazadeh, A. Mehrabi, J. Kiani
The International Journal of Artificial Organs, 2024

Morphine’s Effects on the CNS
The effects of morphine administration on the central nervous system (CNS): advantages and disadvantages
A. Mehrabi, BL Aghaee, S. Farrokhfar
Neuroscience Research Notes 7 (2), 2024

Conclusion

Dr. Arezou Mehrabi is an exceptional candidate for the Best Researcher Award, with extensive expertise in tissue engineering and biomedical science. Her dedication to pioneering research in tissue engineering, particularly in wound healing and cardiac applications, as well as her solid publication and patent record, highlight her as a leading scientist in her field. While there are areas where expanding international collaboration and public outreach could further amplify her impact, Dr. Mehrabi’s innovative approach, academic accomplishments, and contributions to practical medical solutions make her highly deserving of recognition as a top researcher.

Liza Takiya | Dermatology | Business and Academic Collaboration Award

Posted on by ScienceFather

Dr. Liza Takiya | Dermatology | Business and Academic Collaboration Award

Senior Medical Director. Pfizer, United States

A seasoned professional with over 25 years of experience in clinical internal medicine and the pharmaceutical industry, specializing in dermatology, rheumatology, neuroscience, pain management, and women’s health. Known for scientific leadership in medical strategy planning and execution, including product launches and advisory boards.  Recognized for building relationships, strategic thinking, and delivering results, leading to multiple awards and promotions throughout a distinguished career.

Profile

scopus

Education🎓

Doctor of Pharmacy from the University of Maryland, 1997.  Completed an ASHP Accredited Ambulatory Care/Community Practice Residency at the University of Maryland School of Pharmacy, 1997-1998.  Pre-Pharmacy studies at the University of Maryland, College Park, 1991-1993.  Participated in numerous management and leadership training programs, enhancing skills in executive coaching and women in leadership.

Experience💼 

Currently a Senior Director of US Medical Affairs in Dermatology at Pfizer Inc., with previous roles in Global Product Development and various leadership positions in Medical Affairs.  Served as an Associate Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia, fostering the next generation of pharmacy leaders. 🏥 Prior experience includes roles at CVS Pharmacy, enhancing clinical pharmacy practice across Maryland and Pennsylvania.

Awards and Honors🏆

Fellow of the College of Clinical Pharmacy, awarded in 2010. 🌟 Completed multiple prestigious leadership programs, including the LandIt Executive Coaching in 2021 and Florida International University Women Leaders Program in 2020.  Received various internal awards for exemplary performance and contributions in medical affairs at Pfizer. 🎖 Recognized for her commitment to advancing women’s leadership in pharmacy and healthcare.

Research Focus🔬

Focused on medical strategy development and execution in dermatology, rheumatology, and neuroscience.  Research interests include product launches, field training, medical content creation, and clinical guidelines.  Committed to enhancing patient care through innovative pharmaceutical solutions and impactful educational initiatives.  Engages in community development through research and training aimed at addressing healthcare disparities.

Conclusion

In summary, the candidate is highly suitable for the Research for Business and Academic Collaboration Award due to their extensive clinical and pharmaceutical experience, demonstrated leadership, and commitment to education. While there are areas for improvement, such as expanding their research network and enhancing publication efforts, their strengths outweigh these areas. The candidate’s potential to drive impactful collaborations between academia and industry makes them a deserving nominee for this award.

Publication

1. Efficacy and Safety of Ritlecitinib in Alopecia Totalis and Alopecia Universalis

Authors: Mesinkovska, N., King, B., Zhang, X., Wolk, R., Schaefer, G.
Journal: Journal of Dermatology, 2024
Overview: This study evaluates the efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, specifically in adolescents and adults suffering from alopecia totalis and universalis. The findings indicate promising outcomes in hair regrowth and tolerability, marking a significant advancement in treatment options for severe forms of alopecia.
Citations: 0

2. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata

Authors: Hordinsky, M., Hebert, A.A., Gooderham, M., Wolk, R., Tran, H.
Journal: Pediatric Dermatology, 2023, 40(6), pp. 1003–1009
Overview: This article reports on the results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial, highlighting the effectiveness of ritlecitinib in treating adolescents with alopecia areata. The study reveals significant improvements in hair regrowth compared to the placebo group.
Citations: 14

3. Overview of Alopecia Areata for Managed Care and Payer Stakeholders

Authors: King, B., Pezalla, E., Fung, S., Takiya, L., Napatalung, L.
Journal: Journal of Managed Care and Specialty Pharmacy, 2023, 29(7), pp. 848–856
Overview: This review addresses the implications of alopecia areata from a managed care perspective, discussing treatment options, economic considerations, and the importance of awareness among payer stakeholders regarding the condition.
Citations: 1

4. Impact of Crisaborole on Sleep Outcomes in Pediatric Patients

Authors: Fowler, J., Sugarman, J., Sher, L., Marfo, A.A., Takiya, L.
Journal: Dermatology and Therapy, 2023, 13(4), pp. 951–960
Overview: This study assesses the effects of Crisaborole, a topical medication, on sleep quality in pediatric patients with mild-to-moderate atopic dermatitis. The findings suggest that treatment with Crisaborole may lead to improved sleep outcomes in this demographic.
Citations: 2

5. Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment

Authors: Senna, M., Forman, S., Bordone, L., Ahmed, H.M., Takiya, L.
Journal: SKIN: Journal of Cutaneous Medicine, 2023, 7(4), pp. s224
Overview: This post hoc analysis of the ALLEGRO trial examines hair regrowth in specific areas among patients who did not meet target efficacy responses at Week 24. The results indicate that continued treatment with ritlecitinib may still yield positive hair regrowth outcomes in these patients.
Citations: 0

6. Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis by Baseline BMI

Authors: Dikranian, A.H., Gonzalez-Gay, M.A., Wellborne, F., Tatulych, S., Curtis, J.R.
Journal: RMD Open, 2022, 8(1)
Overview: This article analyzes pooled data from phase 3 studies to assess how baseline body mass index (BMI) affects the efficacy of tofacitinib in treating rheumatoid arthritis, emphasizing the need for personalized treatment approaches.
Citations: 12

7. Efficacy and Safety of Tofacitinib by Background Methotrexate Dose

Authors: Kivitz, A.J., FitzGerald, O., Nash, P., Wang, C., Takiya, L.
Journal: Clinical Rheumatology, 2022, 41(2), pp. 499–511
Overview: This post hoc exploratory analysis examines the relationship between background methotrexate dosage and the efficacy and safety of tofacitinib in patients with psoriatic arthritis, aiming to optimize treatment strategies.
Citations: 8

8. Patient and Caregiver Preferences on Treatment Attributes for Atopic Dermatitis

Authors: Ervin, C., Crawford, R., Evans, E., Takiya, L., Myers, D.E.
Journal: Journal of Dermatological Treatment, 2022, 33(4), pp. 2225–2233
Overview: This study investigates the preferences of patients and caregivers regarding treatment characteristics for atopic dermatitis, highlighting the importance of patient-centered approaches in therapeutic decision-making.
Citations: 13

9. Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use

Authors: Geng, B., Hebert, A.A., Takiya, L., Sanders, P., Lebwohl, M.G.
Journal: Dermatology and Therapy, 2021, 11(5), pp. 1679
Overview: An erratum correcting previously published results on the long-term efficacy and safety of Crisaborole in patients with mild-to-moderate atopic dermatitis.
Citations: 0

10. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use

Authors: Geng, B., Hebert, A.A., Takiya, L., Sanders, P., Lebwohl, M.G.
Journal: Dermatology and Therapy, 2021, 11(5), pp. 1667–1678
Overview: This article reviews the long-term use of Crisaborole in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis, assessing both efficacy and safety profiles.
Citations: 6